Clinical trial
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
NCT00072358 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00072358 |
|---|---|
| Title | Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma |
| Official title | Phase II Study of Anti-GD2 3F8 Antibody and GM-CSF for High-Risk Neuroblastoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | anti-GD2 murine IgG3 monoclonal antibody 3F8 |
| Enrollment | 291 |
| Start date | Jul 1, 2003 |
| Primary completion | Jan 15, 2021 |
| Completion | Jan 15, 2021 |
| First posted | Nov 6, 2003 |
| Last update posted | May 16, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: